|
| FGF23在慢性肾脏病心血管并发症中的研究进展 |
| The research progress of FGF23 in cardiovascular complications of chronic kidney disease |
| 投稿时间：2024-11-14 修订日期：2025-04-18 |
| DOI： |
| 中文关键词: 成纤维细胞生长因子23 慢性肾脏病 血管钙化 左心室肥大 心肌纤维化 心律失常 心力衰竭 靶向治疗 |
| 英文关键词: Fibroblast growth factor 23 Chronic kidney disease Vascular calcification Left ventricular hypertrophy Myocardial fibrosis Arrhythmia Heart failure Targeted therapy |
| 基金项目:无 |
|
| 摘要点击次数: 31 |
| 全文下载次数: 0 |
| 中文摘要: |
| 成纤维细胞生长因子23（fibroblast growth factor 23,FGF23）是一种骨源性磷酸盐激素，在调节磷酸盐代谢和维生素 D 稳态中起着至关重要的作用。最近的研究表明，高血清浓度的FGF23与慢性肾脏病（Chronic kidney disease, CKD）的进展及其心血管并发症相关，包括血管钙化、左心室肥大、心肌纤维化、心律失常和心力衰竭等，故FGF23有望成为治疗CKD心血管并发症的潜在靶点。目前一些研究表明通过降低高循环浓度的FGF23、抑制FGF23的生成及抑制其下游靶点FGFR4在一定程度上可延缓CKD心血管并发症的进展。本文就FGF23与CKD心血管并发症的关系和治疗的研究结果进行综述。 |
| 英文摘要: |
| Fibroblast growth factor 23 (FGF23) is a bone-derived phosphate hormone that plays a crucial role in the regulation of phosphate metabolism and vitamin D homeostasis. Recent studies have shown that high serum concentrations of FGF23 are associated with the progression of chronic kidney disease (CKD) and its cardiovascular complications, including vascular calcification, left ventricular hypertrophy, myocardial fibrosis, arrhythmia, and heart failure，so FGF23 could be a potential target for the treatment of cardiovascular complications in CKD. Some studies have shown that reducing the high circulating concentration of FGF23, inhibiting the generation of FGF23, and inhibiting its downstream target FGFR4 can delay the progression of cardiovascular complications in CKD to some extent. This article reviews the results of studies on the relationship and treatment between FGF23 and cardiovascular complications in CKD. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |
